For the year ending 2025-12-31, VTRS has $37,193,100K in assets. $22,481,800K in debts. $1,322,400K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,322,400 | 734,800 | 991,900 | 1,259,900 |
| Accounts receivable, net | 3,031,300 | 3,221,300 | 3,700,400 | 3,814,500 |
| Inventories | 3,999,200 | 3,854,100 | 3,469,700 | 3,519,500 |
| Prepaid expenses | 225,400 | 140,900 | 155,900 | 194,600 |
| Deferred consideration due from biocon biologics-Biocon Biologics-Other Current Assets | - | 0 | 321,200 | - |
| Available-for-sale fixed income securities | 40,700 | 38,000 | 37,000 | 35,300 |
| Fair value of financial instruments | 84,200 | 261,600 | 106,200 | 134,700 |
| Equity securities | 65,700 | 55,500 | 49,300 | 42,600 |
| Deferred charge for taxes on intercompany profit | 568,300 | 526,600 | 747,300 | - |
| Income tax receivable | 315,800 | 300,700 | 340,200 | - |
| Other current assets | 136,200 | 387,200 | 271,000 | 1,404,000 |
| Prepaid expenses and other current assets | 1,436,300 | 1,710,500 | 2,028,100 | 1,811,200 |
| Assets held for sale | - | 0 | 2,786,000 | 230,300 |
| Total current assets | 9,789,200 | 9,520,700 | 12,976,100 | 10,635,400 |
| Property, plant and equipment, gross | 5,134,700 | 4,869,300 | 4,770,300 | 5,083,800 |
| Accumulated depreciation | 2,520,700 | 2,203,200 | 2,010,700 | 2,059,300 |
| Property, plant and equipment, net | 2,614,000 | 2,666,100 | 2,759,600 | 3,024,500 |
| Finite-lived intangible assets, original cost | 34,506,800 | 33,348,500 | 34,178,100 | 37,490,500 |
| In-process research and development | 706,000 | 814,200 | 319,400 | 40,200 |
| Intangible assets, gross, excluding goodwill | 35,212,800 | 34,162,700 | 34,497,500 | 37,530,700 |
| Finite-lived intangible assets, accumulated amortization | 20,110,700 | 17,091,800 | 15,316,400 | 14,923,600 |
| Intangible assets, net | 15,102,100 | 17,070,900 | 19,181,100 | 22,607,100 |
| Goodwill | 6,754,700 | 9,133,300 | 9,867,100 | 10,425,800 |
| Deferred income tax benefit | 1,061,200 | 753,000 | 692,900 | 925,900 |
| Other assets | 1,871,900 | 2,356,900 | 2,208,700 | 2,403,500 |
| Total assets | 37,193,100 | 41,500,900 | 47,685,500 | 50,022,200 |
| Accounts payable | 1,754,100 | 1,853,700 | 1,938,200 | 1,766,600 |
| Short-term borrowings | - | - | - | 0 |
| Income taxes payable | 124,000 | 192,700 | 226,800 | 279,600 |
| Current portion of long-term debt and other long-term obligations | 1,933,300 | 8,300 | 1,943,400 | 1,259,100 |
| Liabilities held for sale | - | 0 | 275,100 | - |
| Other current liabilities | 3,282,900 | 3,724,700 | 3,393,900 | 3,440,900 |
| Total current liabilities | 7,094,300 | 5,779,400 | 7,777,400 | 6,746,200 |
| Long-term debt | 12,480,600 | 14,038,900 | 16,188,100 | 18,015,200 |
| Deferred income tax liability | 892,000 | 1,107,900 | 1,735,700 | 2,432,000 |
| Other long-term obligations | 2,014,900 | 1,939,200 | 1,516,900 | 1,756,500 |
| Total liabilities | 22,481,800 | 22,865,400 | 27,218,100 | 28,949,900 |
| Common stock 0.01 par value, 3,000,000,000 shares authorized shares issued 1,245,391,929 as of december31, 2025 and 1,234,131,491 as of december31, 2024 | 12,500 | 12,300 | 12,200 | 12,100 |
| Additional paid-in capital | 18,801,300 | 18,921,600 | 18,814,700 | 18,645,800 |
| Retained (deficit) earnings | -388,300 | 3,418,800 | 4,639,700 | 5,175,600 |
| Accumulated other comprehensive loss | -2,707,000 | -3,212,900 | -2,747,400 | -2,761,200 |
| Stockholders equity parent before treasury stock | 15,718,500 | 19,139,800 | 20,719,200 | - |
| Less treasury stock - at cost | 1,007,200 | 504,300 | 251,800 | - |
| Total equity | 14,711,300 | 18,635,500 | 20,467,400 | 21,072,300 |
| Total liabilities and equity | 37,193,100 | 41,500,900 | 47,685,500 | 50,022,200 |
Viatris Inc (VTRS)
Viatris Inc (VTRS)